Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Clinical Laboratory Management(Electronic Edition) ›› 2020, Vol. 08 ›› Issue (04): 220-223. doi: 10.3877/cma.j.issn.2095-5820.2020.04.007

Special Issue:

• Clinical Research • Previous Articles     Next Articles

The application values of PIVKA-Ⅱ in diagnosing the hepatitis-related carcinoma

Hao Xi1, Rongjing Liu1,()   

  1. 1. Department of Clinical Laboratory, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China
  • Received:2020-06-17 Online:2020-11-28 Published:2020-11-28
  • Contact: Rongjing Liu
  • About author:
    Corresponding author:Liu Rongjing, Email:

Abstract:

Objective

To investigate the value of abnormal prothrombin in the diagnosis of hepatitis B related hepatocellular carcinoma (HCC) and provide experimental evidence for its clinical application.

Methods

The serum levels of PIVKA-Ⅱand alpha-fetoprotein in healthy subjects, hepatitis B-related benign diseases, and hepatitis B related hepatocellular carcinoma were measured, which had no abnormal coagulation function. ROC curves were used to analyze the value of the two methods in combination and unitaryin the diagnosis of hepatitis B related hepatocellular carcinoma.

Results

PIVKA-Ⅱwas significantly higher in patients with hepatitis B related hepatocellular carcinoma than in healthy controls and benign liver diseases (P<0.05). The area under the ROC curve was 0.940; the sensitivity of the combined detection of AFP and hepatitis B was 94.9%, the specificity was 68.3%. The area under the curve of the combination was 0.947.

Conclusion

PIVKA-Ⅱhas diagnostic value for hepatitis B related HCC, and its combined detection with AFP is more advantageous for the diagnosis of hepatitis B related HCC.For diagnostic use, PIVKA-Ⅱis most cost-effective in at-risk patients with normal levels of AFP in serum.

Key words: PIVKA-Ⅱ, AFP, Hepatitis B related hepatocellular carcinoma

京ICP 备07035254号-20
Copyright © Chinese Journal of Clinical Laboratory Management(Electronic Edition), All Rights Reserved.
Tel: 020-81341720 Fax: 020-37103505 E-mail: clinlab@cma.org.cn
Powered by Beijing Magtech Co. Ltd